Myasthenia gravis is an autoimmune disease in which antibodies interfere with neuromuscular transmission, most commonly by targeting nicotinic acetylcholine receptors and, in some patients, proteins such as MuSK. The classic result is fatigable skeletal-muscle weakness that worsens with activity.